Transthyretin Amyloidosis (ATTR) Market, Global Outlook and Forecast 2022-2028
Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point mutations within TTR allele, wild-type ATTR is caused by the misfolding of Wild-Type TTR. Major prevalence of Hereditary ATTR is observed in the 7MM, and this type has been further sub-classified into Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis Cardiomyopathy (FAC).
This report contains market size and forecasts of Transthyretin Amyloidosis (ATTR) in Global, including the following market information:
Global Transthyretin Amyloidosis (ATTR) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Transthyretin Amyloidosis (ATTR) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hereditary ATTR (HATTR) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Transthyretin Amyloidosis (ATTR) include Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Corino Therapeutics, Proclara Bioscience and Arcturus Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Transthyretin Amyloidosis (ATTR) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Transthyretin Amyloidosis (ATTR) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Transthyretin Amyloidosis (ATTR) Market Segment Percentages, by Type, 2021 (%)
Global Transthyretin Amyloidosis (ATTR) Market Segment Percentages, by Application, 2021 (%)
Global Transthyretin Amyloidosis (ATTR) Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Transthyretin Amyloidosis (ATTR) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Transthyretin Amyloidosis (ATTR) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
This report contains market size and forecasts of Transthyretin Amyloidosis (ATTR) in Global, including the following market information:
Global Transthyretin Amyloidosis (ATTR) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Transthyretin Amyloidosis (ATTR) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hereditary ATTR (HATTR) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Transthyretin Amyloidosis (ATTR) include Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Corino Therapeutics, Proclara Bioscience and Arcturus Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Transthyretin Amyloidosis (ATTR) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Transthyretin Amyloidosis (ATTR) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Transthyretin Amyloidosis (ATTR) Market Segment Percentages, by Type, 2021 (%)
- Hereditary ATTR (HATTR)
- Wild-Type (WT) ATTR
Global Transthyretin Amyloidosis (ATTR) Market Segment Percentages, by Application, 2021 (%)
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers
Global Transthyretin Amyloidosis (ATTR) Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Transthyretin Amyloidosis (ATTR) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Transthyretin Amyloidosis (ATTR) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Pfizer
- Alnylam Pharmaceuticals
- Ionis Pharmaceuticals
- Corino Therapeutics
- Proclara Bioscience
- Arcturus Therapeutics
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Transthyretin Amyloidosis (ATTR) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Transthyretin Amyloidosis (ATTR) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL TRANSTHYRETIN AMYLOIDOSIS (ATTR) OVERALL MARKET SIZE
2.1 Global Transthyretin Amyloidosis (ATTR) Market Size: 2021 VS 2028
2.2 Global Transthyretin Amyloidosis (ATTR) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Transthyretin Amyloidosis (ATTR) Players in Global Market
3.2 Top Global Transthyretin Amyloidosis (ATTR) Companies Ranked by Revenue
3.3 Global Transthyretin Amyloidosis (ATTR) Revenue by Companies
3.4 Top 3 and Top 5 Transthyretin Amyloidosis (ATTR) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Transthyretin Amyloidosis (ATTR) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Transthyretin Amyloidosis (ATTR) Players in Global Market
3.6.1 List of Global Tier 1 Transthyretin Amyloidosis (ATTR) Companies
3.6.2 List of Global Tier 2 and Tier 3 Transthyretin Amyloidosis (ATTR) Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Transthyretin Amyloidosis (ATTR) Market Size Markets, 2021 & 2028
4.1.2 Hereditary ATTR (HATTR)
4.1.3 Wild-Type (WT) ATTR
4.2 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue & Forecasts
4.2.1 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2022
4.2.2 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue, 2023-2028
4.2.3 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Transthyretin Amyloidosis (ATTR) Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Ambulatory Surgical Centers
5.1.4 Diagnostic Centers
5.2 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue & Forecasts
5.2.1 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2022
5.2.2 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue, 2023-2028
5.2.3 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Transthyretin Amyloidosis (ATTR) Market Size, 2021 & 2028
6.2 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue & Forecasts
6.2.1 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2022
6.2.2 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue, 2023-2028
6.2.3 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028
6.3.2 US Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.3.3 Canada Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.3.4 Mexico Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028
6.4.2 Germany Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.3 France Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.4 U.K. Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.5 Italy Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.6 Russia Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.7 Nordic Countries Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.8 Benelux Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028
6.5.2 China Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.5.3 Japan Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.5.4 South Korea Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.5.5 Southeast Asia Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.5.6 India Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028
6.6.2 Brazil Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.6.3 Argentina Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028
6.7.2 Turkey Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.7.3 Israel Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.7.4 Saudi Arabia Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.7.5 UAE Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Pfizer
7.1.1 Pfizer Corporate Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.1.4 Pfizer Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.1.5 Pfizer Key News
7.2 Alnylam Pharmaceuticals
7.2.1 Alnylam Pharmaceuticals Corporate Summary
7.2.2 Alnylam Pharmaceuticals Business Overview
7.2.3 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.2.4 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.2.5 Alnylam Pharmaceuticals Key News
7.3 Ionis Pharmaceuticals
7.3.1 Ionis Pharmaceuticals Corporate Summary
7.3.2 Ionis Pharmaceuticals Business Overview
7.3.3 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.3.4 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.3.5 Ionis Pharmaceuticals Key News
7.4 Corino Therapeutics
7.4.1 Corino Therapeutics Corporate Summary
7.4.2 Corino Therapeutics Business Overview
7.4.3 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.4.4 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.4.5 Corino Therapeutics Key News
7.5 Proclara Bioscience
7.5.1 Proclara Bioscience Corporate Summary
7.5.2 Proclara Bioscience Business Overview
7.5.3 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.5.4 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.5.5 Proclara Bioscience Key News
7.6 Arcturus Therapeutics
7.6.1 Arcturus Therapeutics Corporate Summary
7.6.2 Arcturus Therapeutics Business Overview
7.6.3 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.6.4 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.6.5 Arcturus Therapeutics Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Transthyretin Amyloidosis (ATTR) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Transthyretin Amyloidosis (ATTR) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL TRANSTHYRETIN AMYLOIDOSIS (ATTR) OVERALL MARKET SIZE
2.1 Global Transthyretin Amyloidosis (ATTR) Market Size: 2021 VS 2028
2.2 Global Transthyretin Amyloidosis (ATTR) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Transthyretin Amyloidosis (ATTR) Players in Global Market
3.2 Top Global Transthyretin Amyloidosis (ATTR) Companies Ranked by Revenue
3.3 Global Transthyretin Amyloidosis (ATTR) Revenue by Companies
3.4 Top 3 and Top 5 Transthyretin Amyloidosis (ATTR) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Transthyretin Amyloidosis (ATTR) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Transthyretin Amyloidosis (ATTR) Players in Global Market
3.6.1 List of Global Tier 1 Transthyretin Amyloidosis (ATTR) Companies
3.6.2 List of Global Tier 2 and Tier 3 Transthyretin Amyloidosis (ATTR) Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Transthyretin Amyloidosis (ATTR) Market Size Markets, 2021 & 2028
4.1.2 Hereditary ATTR (HATTR)
4.1.3 Wild-Type (WT) ATTR
4.2 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue & Forecasts
4.2.1 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2022
4.2.2 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue, 2023-2028
4.2.3 By Type - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Transthyretin Amyloidosis (ATTR) Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Ambulatory Surgical Centers
5.1.4 Diagnostic Centers
5.2 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue & Forecasts
5.2.1 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2022
5.2.2 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue, 2023-2028
5.2.3 By Application - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Transthyretin Amyloidosis (ATTR) Market Size, 2021 & 2028
6.2 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue & Forecasts
6.2.1 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2022
6.2.2 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue, 2023-2028
6.2.3 By Region - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028
6.3.2 US Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.3.3 Canada Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.3.4 Mexico Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028
6.4.2 Germany Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.3 France Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.4 U.K. Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.5 Italy Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.6 Russia Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.7 Nordic Countries Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.4.8 Benelux Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028
6.5.2 China Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.5.3 Japan Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.5.4 South Korea Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.5.5 Southeast Asia Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.5.6 India Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028
6.6.2 Brazil Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.6.3 Argentina Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028
6.7.2 Turkey Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.7.3 Israel Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.7.4 Saudi Arabia Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
6.7.5 UAE Transthyretin Amyloidosis (ATTR) Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Pfizer
7.1.1 Pfizer Corporate Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.1.4 Pfizer Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.1.5 Pfizer Key News
7.2 Alnylam Pharmaceuticals
7.2.1 Alnylam Pharmaceuticals Corporate Summary
7.2.2 Alnylam Pharmaceuticals Business Overview
7.2.3 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.2.4 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.2.5 Alnylam Pharmaceuticals Key News
7.3 Ionis Pharmaceuticals
7.3.1 Ionis Pharmaceuticals Corporate Summary
7.3.2 Ionis Pharmaceuticals Business Overview
7.3.3 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.3.4 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.3.5 Ionis Pharmaceuticals Key News
7.4 Corino Therapeutics
7.4.1 Corino Therapeutics Corporate Summary
7.4.2 Corino Therapeutics Business Overview
7.4.3 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.4.4 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.4.5 Corino Therapeutics Key News
7.5 Proclara Bioscience
7.5.1 Proclara Bioscience Corporate Summary
7.5.2 Proclara Bioscience Business Overview
7.5.3 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.5.4 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.5.5 Proclara Bioscience Key News
7.6 Arcturus Therapeutics
7.6.1 Arcturus Therapeutics Corporate Summary
7.6.2 Arcturus Therapeutics Business Overview
7.6.3 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Major Product Offerings
7.6.4 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue in Global Market (2017-2022)
7.6.5 Arcturus Therapeutics Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Transthyretin Amyloidosis (ATTR) Market Opportunities & Trends in Global Market
Table 2. Transthyretin Amyloidosis (ATTR) Market Drivers in Global Market
Table 3. Transthyretin Amyloidosis (ATTR) Market Restraints in Global Market
Table 4. Key Players of Transthyretin Amyloidosis (ATTR) in Global Market
Table 5. Top Transthyretin Amyloidosis (ATTR) Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Transthyretin Amyloidosis (ATTR) Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Transthyretin Amyloidosis (ATTR) Revenue Share by Companies, 2017-2022
Table 8. Global Companies Transthyretin Amyloidosis (ATTR) Product Type
Table 9. List of Global Tier 1 Transthyretin Amyloidosis (ATTR) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Transthyretin Amyloidosis (ATTR) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Transthyretin Amyloidosis (ATTR) Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Transthyretin Amyloidosis (ATTR) Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Transthyretin Amyloidosis (ATTR) Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Transthyretin Amyloidosis (ATTR) Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Transthyretin Amyloidosis (ATTR) Product Offerings
Table 32. Pfizer Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 33. Alnylam Pharmaceuticals Corporate Summary
Table 34. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product Offerings
Table 35. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 36. Ionis Pharmaceuticals Corporate Summary
Table 37. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product Offerings
Table 38. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 39. Corino Therapeutics Corporate Summary
Table 40. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Product Offerings
Table 41. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 42. Proclara Bioscience Corporate Summary
Table 43. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Product Offerings
Table 44. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 45. Arcturus Therapeutics Corporate Summary
Table 46. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Product Offerings
Table 47. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 1. Transthyretin Amyloidosis (ATTR) Market Opportunities & Trends in Global Market
Table 2. Transthyretin Amyloidosis (ATTR) Market Drivers in Global Market
Table 3. Transthyretin Amyloidosis (ATTR) Market Restraints in Global Market
Table 4. Key Players of Transthyretin Amyloidosis (ATTR) in Global Market
Table 5. Top Transthyretin Amyloidosis (ATTR) Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Transthyretin Amyloidosis (ATTR) Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Transthyretin Amyloidosis (ATTR) Revenue Share by Companies, 2017-2022
Table 8. Global Companies Transthyretin Amyloidosis (ATTR) Product Type
Table 9. List of Global Tier 1 Transthyretin Amyloidosis (ATTR) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Transthyretin Amyloidosis (ATTR) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Transthyretin Amyloidosis (ATTR) Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Transthyretin Amyloidosis (ATTR) Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Transthyretin Amyloidosis (ATTR) Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Transthyretin Amyloidosis (ATTR) Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Transthyretin Amyloidosis (ATTR) Product Offerings
Table 32. Pfizer Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 33. Alnylam Pharmaceuticals Corporate Summary
Table 34. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product Offerings
Table 35. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 36. Ionis Pharmaceuticals Corporate Summary
Table 37. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product Offerings
Table 38. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 39. Corino Therapeutics Corporate Summary
Table 40. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Product Offerings
Table 41. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 42. Proclara Bioscience Corporate Summary
Table 43. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Product Offerings
Table 44. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
Table 45. Arcturus Therapeutics Corporate Summary
Table 46. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Product Offerings
Table 47. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Transthyretin Amyloidosis (ATTR) Segment by Type in 2021
Figure 2. Transthyretin Amyloidosis (ATTR) Segment by Application in 2021
Figure 3. Global Transthyretin Amyloidosis (ATTR) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Transthyretin Amyloidosis (ATTR) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Transthyretin Amyloidosis (ATTR) Revenue in 2021
Figure 8. By Type - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 9. By Application - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 10. By Region - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 11. By Country - North America Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 12. US Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 16. Germany Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 17. France Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 24. China Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 28. India Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 30. Brazil Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 33. Turkey Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Transthyretin Amyloidosis (ATTR) Segment by Type in 2021
Figure 2. Transthyretin Amyloidosis (ATTR) Segment by Application in 2021
Figure 3. Global Transthyretin Amyloidosis (ATTR) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Transthyretin Amyloidosis (ATTR) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Transthyretin Amyloidosis (ATTR) Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Transthyretin Amyloidosis (ATTR) Revenue in 2021
Figure 8. By Type - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 9. By Application - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 10. By Region - Global Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 11. By Country - North America Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 12. US Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 16. Germany Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 17. France Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 24. China Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 28. India Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 30. Brazil Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue Market Share, 2017-2028
Figure 33. Turkey Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Transthyretin Amyloidosis (ATTR) Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
